Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
Previous Symbol
CUSIP75915K10
Phone858-202-6300
Debt
Debt-to-Equity RatioN/A
Current Ratio0.99
Quick Ratio0.99
Price-To-Earnings
Trailing P/E Ratio-0.13
Forward P/E Ratio-0.25
P/E GrowthN/A
Sales & Book Value
Annual Sales$70,000.00
Price / Sales186.25
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.07 per share
Price / Book0.37
Profitability
EPS (Most Recent Fiscal Year)($11.52)
Net Income$-71,900,000.00
Net Margins-75,823.62%
Return on Equity-311.60%
Return on Assets-97.57%
Miscellaneous
Employees63
Outstanding Shares8,750,000
Market Cap$13.48 million
OptionableOptionable
Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions
What is Regulus Therapeutics' stock symbol?
Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."
How were Regulus Therapeutics' earnings last quarter?
Regulus Therapeutics Inc (NASDAQ:RGLS) announced its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($1.18) EPS for the quarter, beating the Zacks' consensus estimate of ($1.25) by $0.07. The biopharmaceutical company earned $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 75,823.62% and a negative return on equity of 311.60%. View Regulus Therapeutics' Earnings History.
When is Regulus Therapeutics' next earnings date?
What price target have analysts set for RGLS?
7 brokers have issued twelve-month price objectives for Regulus Therapeutics' stock. Their predictions range from $0.50 to $2.00. On average, they anticipate Regulus Therapeutics' stock price to reach $1.30 in the next twelve months. This suggests that the stock has a possible downside of 12.8%. View Analyst Price Targets for Regulus Therapeutics.
What is the consensus analysts' recommendation for Regulus Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regulus Therapeutics.
What are Wall Street analysts saying about Regulus Therapeutics stock?
Here are some recent quotes from research analysts about Regulus Therapeutics stock:
- 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (11/10/2018)
- 2. Needham & Company LLC analysts commented, "Regulus announced this morning another revision to the Sanofi collaboration agreement, in which Sanofi has been granted a WW exclusive license to RG-012. Sanofi will now assume control of the development program, including all costs going forward. Regulus will receive $7M upfront and is entitled to $40M in development milestone payments. Regulus had suspended enrollment in the Phase 2 RG-012 program in Alport Syndrome earlier this year in order to conserve cash while renegotiating terms with Sanofi. The transaction extends cash to 2Q19, but under new terms, Regulus will not be receiving any revenue from the program after Phase 2 is completed by Sanofi." (11/6/2018)
- 3. Wedbush analysts commented, "We believe this move will likely create some investor/analyst churn in the near term but will open up capital allocation and capacity to focus on the growing CHCA and CHCI segments in the longer term. Although the sale will likely take a couple quarters to complete, we believe this shift will attract a more consumer focused investor base lead to upside from the weak share performance following the report. As such, we remain BUY rated on PRGO shares." (8/10/2018)
Has Regulus Therapeutics been receiving favorable news coverage?
News stories about RGLS stock have trended very positive on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Regulus Therapeutics earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Regulus Therapeutics' key competitors?
Some companies that are related to Regulus Therapeutics include Avenue Therapeutics (ATXI), Acasti Pharma (ACST), Forward Pharma A/S (FWP), Conatus Pharmaceuticals (CNAT), Trevena (TRVN), Aptevo Therapeutics (APVO), Nemus Bioscience (NMUS), OncoSec Medical (ONCS), Leap Therapeutics (LPTX), Evoke Pharma (EVOK), GT Biopharma (GTBP), Zosano Pharma (ZSAN), DiaMedica Therapeutics (DMCAF), Clearside Biomedical (CLSD) and Neurotrope (NTRP).
Who are Regulus Therapeutics' key executives?
Regulus Therapeutics' management team includes the folowing people:
- Mr. Joseph P. Hagan, Pres, CEO & Director (Age 49)
- Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
- Dr. Timothy Michael Wright, Chief R&D Officer (Age 62)
- Ms. Allison Wey, VP of Investor Relations & Corp. Communications
- Mr. Christopher Aker, VP of Legal Affairs & Corp. Sec.
Who are Regulus Therapeutics' major shareholders?
Regulus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (45.38%), Vanguard Group Inc. (29.88%) and Renaissance Technologies LLC (6.82%). Company insiders that own Regulus Therapeutics stock include Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.
Which major investors are selling Regulus Therapeutics stock?
Which major investors are buying Regulus Therapeutics stock?
RGLS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.
How do I buy shares of Regulus Therapeutics?
Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regulus Therapeutics' stock price today?
One share of RGLS stock can currently be purchased for approximately $1.49.
How big of a company is Regulus Therapeutics?
Regulus Therapeutics has a market capitalization of $13.48 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($11.52) on an earnings per share basis. Regulus Therapeutics employs 63 workers across the globe.
What is Regulus Therapeutics' official website?
How can I contact Regulus Therapeutics?
Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]
MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
